Skip to main content

AKBA

Stock
Health Care
Biotechnology

Performance overview

AKBA Price
Price Chart

Forward-looking statistics

Beta
1.49
Risk
67.34%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

akebia therapeutics, inc. is a biopharmaceutical company headquartered in cambridge, massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (hif) biology. akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. akebia’s global phase 3 program for vadadustat, which includes the pro2tect studies for non-dialysis patients with anemia associated with chronic kidney disease and the inno2vate studies for dialysis-dependent patients, is currently ongoing. for more information, please visit our website at www.akebia.com.

Company info

SectorHealth Care
IndustryBiotechnology
Employees260
Market cap$222.2M

Fundamentals

Enterprise value$1.0B
Revenue$184.9M
Revenue per employee
Profit margin-24.51%
Debt to equity795.72

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.21
Dividend per share
Revenue per share$0.85
Avg trading volume (30 day)$22M
Avg trading volume (10 day)$19M
Put-call ratio

Macro factor sensitivity

Growth-1.9
Credit+8.2
Liquidity+2.5
Inflation-6.2
Commodities-0.5
Interest Rates-2.5

Valuation

Dividend yield0.00%
PEG Ratio-13.92
Price to sales5.14
P/E Ratio-13.92
Enterprise Value to Revenue5.62
Price to book38.51

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates

Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.

Zacks Investment Research (May 8, 2025)
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday.

Benzinga (March 20, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free